RegenoCELL Reports on Patient's Progress

NATICK, Mass., June 9, 2011 /PRNewswire/ -- RegenoCELL Therapeutics, Inc. (OTCBB: RCLL), a leader in adult stem cell therapy, today reported on the progress of one of the patients treated with adult stem cells.  Seventy-four year old George, from Illinois, had his first bypass in 1980.  He had a 2nd bypass in 1990 and a third in 2004.

About a year and a half ago, his physicians told him that he had severe blockage of his arteries and a very low ejection fraction.

"My dad's a fighter and never has given up. So I started doing some research for new heart treatments. I then saw some information on stem cells and how they might be able to help heart patients," said Gus, George's son.

George was treated with adult stem cells manufactured by our foreign subsidiary, Regenocell Laboratories, Ltd. which derives the cells from the patient's blood, and grows these cells outside of the patient for transplantation.

By all counts to the patient and his son, now almost 6 months later, the treatment was a success.

"We first noticed that Dad wasn't getting tired as before.  He was also walking a lot better and longer distances. His condition has improved.  His lab results are better."

About RegenoCELL Therapeutics, Inc.

RegenoCELL Therapeutics, Inc. is a leader in adult stem cell therapy for autologous treatment of patients.  The Company plans to obtain regulatory approval in the United States and the European Community to market its stem cell treatments.  Through its foreign subsidiaries, the company is marketing its stem cell treatments for transplantation in jurisdictions where autologous therapy is permitted.

Since 2005, the company's stem cell therapy has treated over 500 patients.  The typical patient is suffering from congestive heart failure with no treatment options and 3 to 6 months to live or from peripheral artery disease (PAD) and in risk of losing a limb.  After extracting and growing stem cells from the patient's blood, the stem cells are transplanted into the same patient.

Forward-Looking Statements:

Except for historical matters contained herein, statements made in this press release are forward-looking and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.  Without limiting the generality of the foregoing, words such as "may", "will", "to", "plan", "expect", "believe", "anticipate", "intend", "could", "would", "estimate", or "continue" or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements.

Investors and others are cautioned that a variety of factors, including certain risks, may affect our business and cause actual results to differ materially from those set forth in the forward-looking statements.  These risk factors include, without limitation (i) our ability to obtain additional financing; (ii) our ability to control our expenses; (iii) our ability through our wholly owned foreign subsidiaries to manufacture and market our stem cell treatments; (iv) our ability to initiate and timely complete clinical trials; (v) the timing of and our ability to obtain and maintain regulatory approvals for our stem cell treatments; (vi) our dependence on the success of our lead stem cell treatment; (vii) our ability to protect our intellectual property rights; and, (viii) intense competition.  The Company is also subject to the risks and uncertainties described in our filings with the Securities and Exchange Commission, including the section entitled "Risk Factors" in its Annual Report on Form 10-K for the year ended December 31, 2010 and its Quarterly Report on Form 10-Q for the quarter ended March 31, 2011.

SOURCE RegenoCELL Therapeutics, Inc.